Ashland Inc. (NYSE:ASH)

Ashland Inc. ASH

Basic Materials - Chemicals - Specialty - NYSE - US

Watchlist

$ 76.96

-1.4 %

$ 3.76 B

Market Cap

19.48

P/E

1. INTRINSIC VALUE

Ashland Inc. provides additives and specialty ingredients worldwide. It operates through Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions. The Personal Care & Household segment provides a range of nature-based, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers.[ Read More ]

The intrinsic value of one ASH stock under the base case scenario is HIDDEN Compared to the current market price of 77 USD, Ashland Inc. is HIDDEN

ASH Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart ASH

FINANCIALS

Annual
Quarterly

3.61 B REVENUE

Growth Rates

1Year 64.67%

3Years 19.56%

5Years 7.67%

7Years 1.46%

10Years -5.15%

-26 M OPERATING INCOME

Growth Rates

1Year -15.12%

3Years -4.58%

5Years -2.95%

7Years -2.43%

10Years -4.58%

169 M NET INCOME

Growth Rates

1Year -5.06%

3Years -8.42%

5Years -19.66%

7Years 29.28%

10Years -3.16%

462 M OPERATING CASH FLOW

Growth Rates

1Year 90.12%

3Years -6.21%

5Years 13.90%

7Years 3.42%

10Years -3.25%

-137 M INVESTING CASH FLOW

Growth Rates

1Year -25.69%

3Years 28.89%

5Years -3.04%

7Years 25.92%

10Years -0.91%

-479 M FINANCING CASH FLOW

Growth Rates

1Year -29.11%

3Years -3.99%

5Years 16.05%

7Years -23.96%

10Years 7.41%

870 M REVENUE

Growth Rates

1Year 64.67%

3Years 19.56%

5Years 7.67%

7Years 1.46%

10Years -5.15%

32 M OPERATING INCOME

Growth Rates

1Year -15.12%

3Years -4.58%

5Years -2.95%

7Years -2.43%

10Years -4.58%

16 M NET INCOME

Growth Rates

1Year -5.06%

3Years -8.42%

5Years -19.66%

7Years 29.28%

10Years -3.16%

80 M OPERATING CASH FLOW

Growth Rates

1Year 90.12%

3Years -6.21%

5Years 13.90%

7Years 3.42%

10Years -3.25%

-37 M INVESTING CASH FLOW

Growth Rates

1Year -25.69%

3Years 28.89%

5Years -3.04%

7Years 25.92%

10Years -0.91%

-170 M FINANCING CASH FLOW

Growth Rates

1Year -29.11%

3Years -3.99%

5Years 16.05%

7Years -23.96%

10Years 7.41%

Balance Sheet Decomposition Ashland Inc.

5.94 B ASSETS
2.84 B LIABILITIES

Current Assets	1.51 B
Cash & Short-Term Investments	417 M
Receivables	338 M
Other Current Assets	751 M
Non-Current Assets	4.43 B
Long-Term Investments	435 M
PP&E	1.5 B
Other Non-Current Assets	2.5 B

Current Liabilities	456 M
Accounts Payable	210 M
Short-Term Debt	38 M
Other Current Liabilities	208 M
Non-Current Liabilities	2.39 B
Long-Term Debt	1.42 B
Other Non-Current Liabilities	966 M

EFFICIENCY

Earnings Waterfall Ashland Inc.

Revenue	3.61 B
Cost Of Revenue	2.99 B
Gross Profit	618 M
Operating Expenses	459 M
Operating Income	-26 M
Other Expenses	-195 M
Net Income	169 M

RATIOS

17.13% GROSS MARGIN

Averages

1Year 17.13%

3Years 27.44%

5Years 28.89%

7Years 29.14%

10Years 29.33%

-0.72% OPERATING MARGIN

Averages

1Year -0.72%

3Years 5.81%

5Years 10.89%

7Years 9.60%

10Years 8.66%

-3.19% NET MARGIN

Averages

1Year -3.19%

3Years 4.17%

5Years -0.08%

7Years 0.51%

10Years 0.88%

0.00% ROE

Averages

1Year 0.00%

3Years 3.79%

5Years 0.30%

7Years 0.79%

10Years 1.48%

0.00% ROA

Averages

1Year 0.00%

3Years 1.97%

5Years 0.28%

7Years 0.44%

10Years 0.59%

0.00% ROIC

Averages

1Year 0.00%

3Years 2.96%

5Years 5.40%

7Years 4.52%

10Years 4.19%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Ashland Inc.

Net Income	169 M
Depreciation & Amortization	274 M
Capital Expenditures	-137 M
Stock-Based Compensation	15 M
Change in Working Capital	0
Others	306 M
Free Cash Flow	325 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Ashland Inc.

Wall Street analysts predict an average 1-year price target for ASH of $109 , with forecasts ranging from a low of $92 to a high of $126 .

ASH Lowest Price Target Wall Street Target

92 USD 19.54%

ASH Average Price Target Wall Street Target

109 USD 41.26%

ASH Highest Price Target Wall Street Target

126 USD 63.72%

4. DIVIDEND ANALYSIS

0.47% DIVIDEND YIELD

0.405 USD DIVIDEND PER SHARE

5. COMPETITION

H.B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives, and other specialty chemical products worldwide.

31.7 USD

FUL

Overvalued 58.22%

Element Solutions Inc operates as a specialty chemicals company in the United States, China, and internationally. The company operates in two segments, Electronics, and Industrial & Specialty.

11.3 USD

ESI

Overvalued 59.82%

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally.

159 USD

BCPC

Overvalued 10.73%

Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.

13.9 USD

AVTR

Overvalued 32.83%

Minerals Technologies Inc. develops, produces, and markets various specialty mineral, mineral-based, and synthetic mineral products, and supporting systems and services. The company operates through three segments: Performance Materials, Specialty Minerals and Refractories.

59.9 USD

MTX

Overvalued 25.69%

Axalta Coating Systems Ltd., through its subsidiaries, manufactures, markets, and distributes high-performance coatings systems in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.

24.7 USD

AXTA

Overvalued 38.82%

Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally.

125 USD

IOSP

Undervalued 4.76%

Oil-Dri Corporation of America, together with its subsidiaries, develops, manufactures, and markets sorbent products in the United States and internationally. It operates in two segments, Retail and Wholesale Products Group; and Business to Business Products Group.

49.7 USD

ODC

Overvalued 26.98%

Quaker Chemical Corporation develops, produces, and markets various formulated chemical specialty products for a range of heavy industrial and manufacturing applications.

174 USD

KWR

Undervalued 3.84%

Sensient Technologies Corporation, together with its subsidiaries, develops, manufactures, and markets colors, flavors, and other specialty ingredients in North America, Europe, the Asia Pacific, and internationally.

35.8 USD

SXT

Overvalued 53.49%

6. Ownership

Insider Ownership Ashland Inc.

Summary
Transactions

Sold

0-3 MONTHS

482 K USD 1

3-6 MONTHS

0 USD 0

6-9 MONTHS

78.1 K USD 1

9-12 MONTHS

69.4 K USD 1

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
2 months ago Sep 04, 2024	Sell 482 K USD	WILLIS J KEVIN SVP and CFO	- 5487	87.88 USD
9 months ago Feb 16, 2024	Sell 78.1 K USD	LAMPKIN ROBIN E. SVP, Gen Counsel and Secrty.	- 844	92.54 USD
11 months ago Dec 07, 2023	Sell 69.4 K USD	BONI ERIC N Principal Accounting Officer	- 843	82.38 USD
1 year ago Sep 05, 2023	Sell 681 K USD	WILLIS J KEVIN Sr.VP &Chief Financial Officer	- 7866	86.54 USD
2 years ago Sep 01, 2022	Sell 22.5 M USD	Sandler Ricky C director, other: See Remarks	- 224156	100.2 USD
2 years ago Sep 01, 2022	Bought 22.5 M USD	EMINENCE CAPITAL, LP director:	+ 224156	100.2 USD
2 years ago Sep 01, 2022	Sell 22.5 M USD	EMINENCE CAPITAL, LP director:	- 224156	100.2 USD
2 years ago Sep 01, 2022	Bought 22.5 M USD	Sandler Ricky C director, other: See Remarks	+ 224156	100.2 USD
2 years ago Jun 07, 2022	Sell 291 K USD	BONI ERIC N Principal Accounting Officer	- 2657	109.5 USD
2 years ago Jun 02, 2022	Sell 196 K USD	WILLIS J KEVIN Sr.VP &Chief Financial Officer	- 1861	105.58 USD
2 years ago Jun 01, 2022	Sell 251 K USD	WILLIS J KEVIN Sr.VP &Chief Financial Officer	- 2374	105.58 USD
2 years ago May 17, 2022	Bought 4.94 M USD	EMINENCE CAPITAL, LP director:	+ 48800	101.27 USD
2 years ago May 17, 2022	Bought 4.94 M USD	Sandler Ricky C director, other: See Remarks	+ 48800	101.27 USD
3 years ago Sep 10, 2021	Sell 104 K USD	WILLIS J KEVIN Chief Financial Officer	- 1104	94.3 USD
3 years ago Jun 03, 2021	Sell 228 K USD	BONI ERIC N Principal Accounting Officer	- 2429	93.88 USD
3 years ago Dec 28, 2020	Sell 326 K USD	WILLIS J KEVIN Chief Financial Officer	- 4074	80 USD
3 years ago Nov 30, 2020	Sell 194 K USD	Ganz Peter Senior Vice President	- 2549	75.93 USD
3 years ago Nov 24, 2020	Bought 7.79 K USD	KALYANA SWAMINATHAN ASHOK Sr VP & Gen Mgr, Life Sciences	+ 100	77.88 USD
4 years ago Nov 18, 2020	Sell 99.8 K USD	WILLIS J KEVIN Chief Financial Officer	- 1247	80 USD
4 years ago Nov 18, 2020	Sell 76.4 K USD	WILLIS J KEVIN Chief Financial Officer	- 955	80 USD

7. News

Ashland board authorizes quarterly dividend WILMINGTON, Del., Nov. 14, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on December 15, 2024, to stockholders of record at the close of business on December 1, 2024. globenewswire.com - 3 days ago

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria globenewswire.com - 4 days ago

Ashland's Earnings Miss in Q4, Revenues Surpass Estimates ASH sees higher sales volumes in Personal Care, Specialty Additives and Intermediates segments in Q4. zacks.com - 4 days ago

Ashland Place Completes New Financing Facility for Crestone Air Partners, Air T, Inc. and Mill Road Capital NEW YORK , Nov. 12, 2024 /PRNewswire/ -- Ashland Place Finance LLC ("Ashland Place"), a commercial aviation financing platform, today announced the completion of a new facility financing the acquisition of a Boeing 737-800 for Crestone Air Partners, Inc. ("Crestone"), Air T, Inc. ("Air T") and Mill Road Capital Management LLC ("Mill Road"). This is the third transaction that the Ashland Place platform has completed with Crestone, having previously financed the acquisitions of three Boeing 737-800 freighters in January 2024 and four CFM56 engines in July 2022. prnewswire.com - 4 days ago

Ashland Inc. (ASH) Q4 2024 Earnings Call Transcript Ashland Inc. (NYSE:ASH ) Q4 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - SVP and CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo James Cannon - UBS John Roberts - Mizuho Mike Harrison - Seaport Research Partners Operator Thank you for standing by. My name is Hermione and I will be your conference operator today. seekingalpha.com - 1 week ago

Ashland to host live 2024 strategy update event for analysts and investors WILMINGTON, Del., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host a strategy update event for analysts and investors on Tuesday, December 10, 2024, in New York City. The company will provide an in-depth review of Ashland's strategic priorities, key initiatives and financial objectives while emphasizing a proactive approach to market uncertainty in fiscal year 2025. globenewswire.com - 1 week ago

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study globenewswire.com - 1 week ago

Ashland (ASH) Reports Q4 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Ashland (ASH) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 week ago

Ashland (ASH) Q4 Earnings Lag Estimates Ashland (ASH) came out with quarterly earnings of $1.26 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.41 per share a year ago. zacks.com - 1 week ago

Unveiling Ashland (ASH) Q4 Outlook: Wall Street Estimates for Key Metrics Evaluate the expected performance of Ashland (ASH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 1 week ago

Ashland (ASH) Reports Next Week: Wall Street Expects Earnings Growth Ashland (ASH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago

Ashland sets date for fourth-quarter fiscal 2024 earnings release and conference call webcast WILMINGTON, Del., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced plans to issue its fourth-quarter fiscal 2024 earnings release at approximately 5 p.m. ET on Wednesday, November 6, 2024. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Thursday, November 7. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com . globenewswire.com - 2 weeks ago

8. Profile Summary

Ashland Inc. ASH

COUNTRY US

INDUSTRY Chemicals - Specialty

MARKET CAP $ 3.76 B

Dividend Yield 0.47%

Description Ashland Inc. provides additives and specialty ingredients worldwide. It operates through Life Sciences; Personal Care & Household; Specialty Additives; and Intermediates and Solvents segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions. The Personal Care & Household segment provides a range of nature-based, biodegradable, and performance ingredients; solutions for toothpastes, mouth washes and rinses, denture cleaning, and care for teeth; and household supplies nature-derived rheology ingredients, biodegradable surface wetting agents, performance encapsulates, and specialty polymers. The Specialty Additives segment offers rheology modifiers, foam control agents, surfactants and wetting agents, pH neutralizers, advanced ceramics used in catalytic converters, environmental filters, ingredients for the manufacturing of ceramic capacitors, plasma display panels and solar cells, ingredients for textile printing, thermoplastic metals, and alloys for welding. The Intermediates and Solvents segment produces 1,4 butanediol and related derivatives, including n-methylpyrrolidone. It offers its products to customers in a range of consumer and industrial markets, such as architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. The company was formerly known as Ashland Global Holdings Inc. Ashland Inc. was founded in 1924 and is based in Wilmington, Delaware.

Contact 8145 Blazer Drive, Wilmington, DE, 19808 https://www.ashland.com

IPO Date March 17, 1980

Employees 3200

Officers Mr. John Kevin Willis Senior Vice President & Chief Financial Officer Mr. Guillermo Novo Chairman & Chief Executive Officer Mr. Karl R. Bostaph Senior Vice President of Operations Ms. Eileen M. Drury Senior Vice President & Chief HR Officer Michael Coppola Treasurer Ms. Alessandra Faccin Assis Senior Vice President and GM of Life Sciences & Intermediates Mr. Eric N. Boni Vice President of Finance & Principal Accounting Officer Ms. Robin E. Lampkin Senior Vice President, General Counsel & Secretary Mr. James Minicucci Senior Vice President & GM of Personal Care Dr. Osama M. Musa Ph.D. Senior Vice President & Chief Technology Officer

Price Chart ASH

Ashland Inc. ASH

Premium Plan

Unlimited Plan